<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04867226</url>
  </required_header>
  <id_info>
    <org_study_id>Effectiveness of colchicine</org_study_id>
    <nct_id>NCT04867226</nct_id>
  </id_info>
  <brief_title>Effectiveness of Colchicine Among Patients With COVID-19 Infection</brief_title>
  <official_title>Effectiveness of Colchicine Among Patients With COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hawler Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hawler Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In November 2019, there were a lot of cases of an acute respiratory illness (then named at&#xD;
      February 11th as COVID_19) which first case was reported in Wuhan, China,The SARS COV-2 had&#xD;
      been spread in a fast way to involve whole world, As it's obvious that Colchicine is a drug&#xD;
      that is most commonly and widely used to treat and prevent acute attacks of Gout, other&#xD;
      crystal induced arthropathy,colchicine has important role in inhibiting activation of NLRP3&#xD;
      inflammasome these lead to decrease cytokine production , aim of study To evaluate whether&#xD;
      colchicine is effective in the treatment of COVID-19 cases. And to measure the effectiveness&#xD;
      of colchicine in alleviating and controlling pulmonary and extra pulmonary complications of&#xD;
      COVID-19&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      this is an open label, randomize control clinical trial ,the participant will be randomly&#xD;
      assign in to two groups ( Group A and Group B), colchicine (group A) will treat with&#xD;
      colchicine tablet alone or add to their Current treatment,Colchicine 0.5 mg twice daily&#xD;
      (reduce to 0.5 mg/day, in patients with low body weight or develop side effects like&#xD;
      gastrointestinal symptoms ),For 14 days or until symptoms subsides, while the control group&#xD;
      will treat according to usual treatment guideline in COVID-19.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2021</start_date>
  <completion_date type="Actual">June 18, 2021</completion_date>
  <primary_completion_date type="Actual">June 18, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>100 Patients will participate for eligibility and enroll in the study, an open labell randomize control clinical trial will held among patients who will infect with COVID-19 in whom they met the inclusion criteria, either treat at home with healthcare advises and follow up or at centres of COVID-19 in ERBIL city ( Rozhawa emergency hospital, Erbil international private hospital) .</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>need for supplemental oxygen</measure>
    <time_frame>14 days following randomization</time_frame>
    <description>number of patients need supplemental oxygen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>14 days following randomization</time_frame>
    <description>number of patients who admit to hospital and duration of stay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>need for invasive mechanical ventilation</measure>
    <time_frame>14 days following randomization</time_frame>
    <description>number of patients need invasive mechanical ventilation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>death rate</measure>
    <time_frame>14 days following randomization</time_frame>
    <description>number of patients who die during randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>oxygen saturation measurement</measure>
    <time_frame>14 days following randomization</time_frame>
    <description>Sp02 measurement by pulse oximetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>musculoskeletal symptoms</measure>
    <time_frame>14 days following randomization</time_frame>
    <description>participants who have back pain and myalgia measure by patient analogue scale of pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in severity marker</measure>
    <time_frame>14 days following randomization</time_frame>
    <description>CRP measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in inflammatory marker</measure>
    <time_frame>14 days following randomization</time_frame>
    <description>ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in severity marker</measure>
    <time_frame>14 days following randomization</time_frame>
    <description>D.Dimer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in marker</measure>
    <time_frame>14 days following randomization</time_frame>
    <description>leukocyte</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effect</measure>
    <time_frame>14 days following randomization</time_frame>
    <description>number of participants who develop adverse effect with treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>colchicine drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participant in this group will be given a colchicine tablet alone or add to their Current treatment, Colchicine 0.5 mg twice daily (reduced to 0.5 mg/day, in patients with low body weight or develop side effect like gastrointestinal symptoms ),For 14 days or until symptoms subsides.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control group will receive usual care COVID-19 treatment according to Iraqi protocol guideline and will not receive colchicine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine 0.5 MG</intervention_name>
    <description>participant will be given a Colchicine regimen in a dose of 0.5mg twice daily for 14 days or until symptoms subsides,those with low body weight and develop side effect like diarrhea and vomiting dose will be reduced and supportive treatment will be given .</description>
    <arm_group_label>colchicine drug</arm_group_label>
    <other_name>colcrys</other_name>
    <other_name>colchicum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>usual care treatment</intervention_name>
    <description>control group will receive usual care COVID-19 treatment according to Iraqi protocol guideline and will not receive colchicine.</description>
    <arm_group_label>usual care</arm_group_label>
    <other_name>treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.patients diagnosed clinically or by RT-PCR in nasopharyngeal swab specimens and/ or lung&#xD;
        involvement confirm by computed tomography scan compatible with COVID-19patients 2.Age&#xD;
        between 18 year and 70 years, 3.body weight &gt; 50 kg, 4.with written informed consent from&#xD;
        patients or relatives.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria 1 sensitivity to any medications of regimens, 2.e GFR less than 30.&#xD;
        3.pregnancy. 4.malignancy . 5.Participating in another clinical study and refusing to&#xD;
        participate in the study at a later date or later, and they are already taking colchicine&#xD;
        for other diseases .&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dashty Albustany, MBChB.FRCP</last_name>
    <role>Study Director</role>
    <affiliation>assistant professor in medicine,consultant Rheumatologist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aryan MF Jalal</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.B.CH.B, doctor Rheumatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hawler medical university ,Rozhawa emergency hospital</name>
      <address>
        <city>Erbil</city>
        <zip>44001</zip>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <reference>
    <citation>Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol. 2020 Apr;92(4):401-402. doi: 10.1002/jmv.25678. Epub 2020 Feb 12.</citation>
    <PMID>31950516</PMID>
  </reference>
  <reference>
    <citation>Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med. 2020 Jun 1;217(6). pii: e20200678. doi: 10.1084/jem.20200678.</citation>
    <PMID>32353870</PMID>
  </reference>
  <reference>
    <citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.</citation>
    <PMID>32192578</PMID>
  </reference>
  <reference>
    <citation>Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994. Erratum in: JAMA Intern Med. 2020 Jul 1;180(7):1031.</citation>
    <PMID>32167524</PMID>
  </reference>
  <reference>
    <citation>Banu N, Panikar SS, Leal LR, Leal AR. Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications. Life Sci. 2020 Sep 1;256:117905. doi: 10.1016/j.lfs.2020.117905. Epub 2020 Jun 3. Review.</citation>
    <PMID>32504757</PMID>
  </reference>
  <reference>
    <citation>Alhogbani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann Saudi Med. 2016 Jan-Feb;36(1):78-80. doi: 10.5144/0256-4947.2016.78.</citation>
    <PMID>26922692</PMID>
  </reference>
  <reference>
    <citation>Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, Ibrahim H, Friedman GH, Thompson C, Alviar CL, Chadow HL, Fishman GI, Reynolds HR, Keller N, Hochman JS. ST-Segment Elevation in Patients with Covid-19 - A Case Series. N Engl J Med. 2020 Jun 18;382(25):2478-2480. doi: 10.1056/NEJMc2009020. Epub 2020 Apr 17.</citation>
    <PMID>32302081</PMID>
  </reference>
  <reference>
    <citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum in: JAMA. 2021 Mar 16;325(11):1113.</citation>
    <PMID>32031570</PMID>
  </reference>
  <reference>
    <citation>Crittenden DB, Lehmann RA, Schneck L, Keenan RT, Shah B, Greenberg JD, Cronstein BN, Sedlis SP, Pillinger MH. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012 Jul;39(7):1458-64. doi: 10.3899/jrheum.111533. Epub 2012 Jun 1.</citation>
    <PMID>22660810</PMID>
  </reference>
  <reference>
    <citation>Slobodnick A, Shah B, Krasnokutsky S, Pillinger MH. Update on colchicine, 2017. Rheumatology (Oxford). 2018 Jan 1;57(suppl_1):i4-i11. doi: 10.1093/rheumatology/kex453. Review.</citation>
    <PMID>29272515</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 25, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>June 19, 2021</last_update_submitted>
  <last_update_submitted_qc>June 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hawler Medical University</investigator_affiliation>
    <investigator_full_name>Aryan Mohamadfatih Jalal</investigator_full_name>
    <investigator_title>Doctor Rheumatollogy</investigator_title>
  </responsible_party>
  <keyword>covid-19, colchicine</keyword>
  <keyword>Erbil,Iraq</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

